p-Waf1/Cip1/CDKN1A p21 Antibody (D-6): sc-377569

p-p21 Waf1/Cip1 Antibody (D-6) is a mouse monoclonal IgG3 kappa light chain antibody that detects Thr 145 phosphorylated p21 Waf1/Cip1 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). anti-p21 Waf1/Cip1 antibody (D-6) is available in a non-conjugated form, allowing for versatile experimental design. p21 Waf1/Cip1 protein plays a crucial role in cell cycle regulation by acting as a potent inhibitor of cyclin-dependent kinases (Cdks), which are essential for the transition between different phases of the cell cycle. When phosphorylated at Thr 145, p21 retains its ability to bind to and inhibit cyclin-Cdk complexes, effectively preventing the phosphorylation of the retinoblastoma protein (Rb), a key step required for the transition from G1 phase to S phase. This inhibition halts cell cycle progression, enabling cells to repair damaged DNA, undergo senescence, or initiate apoptosis in response to stress or oncogenic signals. By coordinating these responses, p21 maintains genomic stability and prevents unchecked cell division. p21 Waf1/Cip1 expression is tightly regulated and induced by wild-type p53, reinforcing its role in tumor suppression. Understanding p21 Waf1/Cip1 phosphorylation dynamics provides critical insights into mechanisms controlling cell proliferation and their dysregulation in cancer. p21 Waf1/Cip1 monoclonal antibody (D-6) serves as an essential tool for exploring regulatory mechanisms of cell cycle arrest and impact of p21 phosphorylation on cellular responses to stress and DNA damage.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

p-Waf1/Cip1/CDKN1A p21 Antibody (D-6) References:

1. Tensile force inhibits the proliferation of human periodontal ligament fibroblasts through Ras-p38 MAPK up-regulation.  |  Kook, SH. and Lee, JC. 2012. J Cell Physiol. 227: 1098-106. PMID: 21567397
2. Critical role of p21 on olaquindox-induced mitochondrial apoptosis and S-phase arrest involves activation of PI3K/AKT and inhibition of Nrf2/HO-1pathway.  |  Li, D., et al. 2017. Food Chem Toxicol. 108: 148-160. PMID: 28757460
3. Autophagy Flux Contributes to Regulation of Components of Eclipta prostrata L. on Cigarette Smoking-Induced Injury of Bronchial Epithelial Cells.  |  Ding, S., et al. 2018. Front Pharmacol. 9: 107. PMID: 29515441
4. Regulation of Eclipta prostrata L. components on cigarette smoking-induced autophagy of bronchial epithelial cells via keap1-Nrf2 pathway.  |  Ding, S., et al. 2018. Environ Toxicol.. PMID: 29726624
5. Ibrutinib as a potential therapeutic option for HER2 overexpressing breast cancer - the role of STAT3 and p21.  |  Prabaharan, CB., et al. 2020. Invest New Drugs. 38: 909-921. PMID: 31375978
6. Akt Regulated Phosphorylation of GSK-3β/Cyclin D1, p21 and p27 Contributes to Cell Proliferation Through Cell Cycle Progression From G1 to S/G2M Phase in Low-Dose Arsenite Exposed HaCat Cells.  |  Chen, Y., et al. 2019. Front Pharmacol. 10: 1176. PMID: 31680960
7. The Cell-Cycle Regulatory Protein p21CIP1/WAF1 Is Required for Cytolethal Distending Toxin (Cdt)-Induced Apoptosis.  |  Shenker, BJ., et al. 2020. Pathogens. 9: PMID: 31906446
8. Genistein Suppresses v-Src-Driven Proliferative Activity by Arresting the Cell-Cycle at G2/M through Increasing p21 Level in Src-Activated Human Gallbladder Carcinoma cells.  |  Ono, M., et al. 2021. Nutr Cancer. 73: 1471-1479. PMID: 32705888
9. Involvement of actin cytoskeletal modifications in the inhibition of triple-negative breast cancer growth and metastasis by nimbolide.  |  Arumugam, A., et al. 2021. Mol Ther Oncolytics. 20: 596-606. PMID: 33768141
10. Expression of phosphorylated p21-activated kinase 4 is associated with aggressive histologic characteristics and poor prognosis in patients with surgically treated renal cell carcinoma.  |  Kang, HW., et al. 2021. Investig Clin Urol. 62: 399-407. PMID: 34085786

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-p-Waf1/Cip1/CDKN1A p21 Antibody (D-6) has 3 citations in a variety of scientific publications.

Primary antibodies like Anti-p-Waf1/Cip1/CDKN1A p21 Antibody (D-6) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

p-Waf1/Cip1/CDKN1A p21 Antibody (D-6) Specifications

Alternate Product Name: p21 Waf1/Cip1

Product Clone Name: D-6

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₃ kappa light chain

Amino Acids: Thr 145

Epitope Target: p21 Waf1/Cip1

Epitope Species: human

Product Reactivity/Detection: Thr 145 phosphorylated p21 Waf1/Cip1

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: canine, porcine and avian

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG₃ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 3 citations in various scientific publications

Available Conjugates/Forms for p-Waf1/Cip1/CDKN1A p21 Antibody (D-6): P: Blocking Peptide

The preferred Waf1/Cip1/CDKN1A p21 antibody is Waf1/Cip1/CDKN1A p21 Antibody (F-5): sc-6246.